Evidence map›Paper›PMID 42022312›Full record

ReviewFrontiers in oncology2026

Radiomics and artificial intelligence in precision radiotherapy for cervical cancer: a narrative review.

Yuxin He, Yuzhou Lu, Lijun Hu

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuxin He *Department of Radiation Oncology, Changzhou Second People's Hospital, Nanjing Medical University, Changzhou, China.
Yuzhou Lu *Department of Radiation Oncology, Changzhou Second People's Hospital, Nanjing Medical University, Changzhou, China.
Lijun HuDepartment of Radiation Oncology, Changzhou Second People's Hospital, Nanjing Medical University, Changzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer (CC) continues to impose a substantial global health burden and remains one of the most prevalent malignancies among women worldwide. Radiotherapy is a cornerstone treatment for locally advanced disease, and its precision critically impacts tumor control and treatment-related toxicity. Within the evolving paradigm of precision oncology, radiomics and artificial intelligence (AI) have emerged as promising tools to personalize radiotherapy by improving target delineation, predicting treatment response, refining prognostic stratification, and facilitating individualized toxicity risk assessment. This narrative review synthesizes and critically appraises the current evidence on the application of radiomics and AI in CC radiotherapy, focusing on three principal domains: automated target volume delineation, prediction of prognosis and treatment response, and forecasting of radiotherapy-induced toxicities. We further evaluate the methodological rigor and translational readiness of existing studies. Despite encouraging technical performance, most available evidence remains retrospective, with limited prospective validation and uncertain impact on clinical decision-making. Clinical implementation is further challenged by imaging heterogeneity, insufficient standardization, and limited model interpretability. Future research should prioritize large-scale multicenter validation, methodological standardization, and prospective evaluation to determine whether radiomics-guided strategies can meaningfully improve patient outcomes and support integration into routine clinical practice.

Indexed as

artificial intelligencecervical cancerprognosisradiomicsradiotherapy

Identifiers

PMID42022312
PMCPMC13095735

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.